{"id":"azilsartan-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL2028661","moleculeType":"Small molecule","molecularWeight":"568.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azilsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues. By blocking angiotensin II signaling, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and reduced sodium retention. This mechanism makes it effective for hypertension management and cardiovascular protection.","oneSentence":"Azilsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:21.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05107960","phase":"","title":"A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-16","conditions":"Hypertension","enrollment":5},{"nctId":"NCT06990204","phase":"PHASE1","title":"Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)","status":"NOT_YET_RECRUITING","sponsor":"Gedeon Richter Plc.","startDate":"2025-06-06","conditions":"Hypertension","enrollment":56},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT05947448","phase":"","title":"Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study","status":"UNKNOWN","sponsor":"Hasten Biopharmaceutical Co., Ltd.","startDate":"2024-01-22","conditions":"Essential Hypertension","enrollment":1215},{"nctId":"NCT03539627","phase":"","title":"Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.","status":"COMPLETED","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2018-11-07","conditions":"Arterial Hypertension, Diabetes Mellitus, Stable Chronic Angina","enrollment":184},{"nctId":"NCT02791438","phase":"PHASE3","title":"A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-08-18","conditions":"Pediatric Hypertension","enrollment":27},{"nctId":"NCT02541669","phase":"PHASE1","title":"A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-11-20","conditions":"Healthy Volunteer","enrollment":64},{"nctId":"NCT02756819","phase":"","title":"International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-18","conditions":"Hypertension","enrollment":1945},{"nctId":"NCT02181816","phase":"","title":"Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey \"Long-term Use Survey\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06-26","conditions":"Hypertension","enrollment":1090},{"nctId":"NCT02100319","phase":"","title":"Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance \"Hypertension Complicated by Diabetes \"","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03-03","conditions":"Hypertension","enrollment":387},{"nctId":"NCT02480764","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-27","conditions":"Essential Hypertension","enrollment":612},{"nctId":"NCT02517866","phase":"PHASE4","title":"Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-07-13","conditions":"Essential Hypertension, Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT02092025","phase":"","title":"Azilsartan Tablets Special Drug Use Surveillance: Long-term Use","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-06-20","conditions":"Hypertension","enrollment":3437},{"nctId":"NCT03042299","phase":"PHASE1","title":"A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-10","conditions":"Japanese Healthy Adult Male Participants","enrollment":14},{"nctId":"NCT02786082","phase":"PHASE1","title":"Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2016-11-01","conditions":"Hypertension","enrollment":29},{"nctId":"NCT02609490","phase":"PHASE3","title":"Azilsartan in Chinese Patients With Mild and Moderate Hypertension","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2015-09","conditions":"Hypertension","enrollment":304},{"nctId":"NCT03652792","phase":"PHASE1","title":"Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-01-22","conditions":"Bioequivalence of Two Azilsartan Formulations","enrollment":60},{"nctId":"NCT01774591","phase":"NA","title":"Effect of Azilsartan on Aldosterone in Postmenopausal Females","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-01","conditions":"Hypertension","enrollment":21},{"nctId":"NCT02079805","phase":"PHASE4","title":"A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06","conditions":"Essential Hypertension Complicated by Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT02277691","phase":"PHASE3","title":"A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-11-07","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT02203916","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-07","conditions":"Hypertension","enrollment":328},{"nctId":"NCT02401464","phase":"PHASE1","title":"A Bioequivalence Study of TAK-536 Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03","conditions":"Japanese Healthy Adult Males","enrollment":52},{"nctId":"NCT02400775","phase":"PHASE4","title":"A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2015-03","conditions":"Essential Hypertension With Stable Angina and Dyslipidemia","enrollment":""},{"nctId":"NCT02451150","phase":"PHASE3","title":"A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08","conditions":"Pediatric Hypertension","enrollment":6},{"nctId":"NCT01762501","phase":"NA","title":"Azilsartan Circadian and Sleep Pressure","status":"COMPLETED","sponsor":"Sogo Rinsho Médéfi Co., Ltd.","startDate":"2012-12","conditions":"Hypertension","enrollment":957},{"nctId":"NCT01496430","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-01","conditions":"Hypertension, Diabetes","enrollment":105},{"nctId":"NCT02407210","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-01","conditions":"Essential Hypertension","enrollment":304},{"nctId":"NCT01078376","phase":"PHASE1","title":"A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults","status":"TERMINATED","sponsor":"Takeda","startDate":"2010-05","conditions":"Hypertension","enrollment":29},{"nctId":"NCT01456169","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Essential Hypertension","enrollment":507},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Safety","enrollment":153},{"nctId":"NCT01985152","phase":"PHASE1","title":"A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2013-09","conditions":"Health","enrollment":62},{"nctId":"NCT00760214","phase":"PHASE3","title":"Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-01","conditions":"Hypertension","enrollment":885},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT01124656","phase":"PHASE3","title":"Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT00762736","phase":"PHASE2","title":"Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-07","conditions":"Diabetes Mellitus","enrollment":704},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Essential Hypertension","enrollment":609},{"nctId":"NCT00847626","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Hypertension","enrollment":1711},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00591578","phase":"PHASE3","title":"Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-12","conditions":"Hypertension","enrollment":984},{"nctId":"NCT00696384","phase":"PHASE3","title":"A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":418},{"nctId":"NCT00696241","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":1275},{"nctId":"NCT00591266","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":566},{"nctId":"NCT00591773","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-09","conditions":"Hypertension","enrollment":551},{"nctId":"NCT00591253","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":413},{"nctId":"NCT00696436","phase":"PHASE3","title":"An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Hypertension","enrollment":1291},{"nctId":"NCT00695955","phase":"PHASE3","title":"One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":669},{"nctId":"NCT00362115","phase":"PHASE2","title":"Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Hypertension","enrollment":449},{"nctId":"NCT01289132","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":926},{"nctId":"NCT00376181","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-06","conditions":"Type 2 Diabetes","enrollment":96},{"nctId":"NCT00759551","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-08","conditions":"Hypertension","enrollment":555}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Azilsartan tablets","genericName":"Azilsartan tablets","companyName":"Lee's Pharmaceutical Limited","companyId":"lee-s-pharmaceutical-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azilsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}